By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Poxel SAS 

200 avenue Jean Jaures

Lyon    69007  France
Phone: 33-4-37-372010 Fax: 33-4-37-708815



Company News
Poxel Has Been Granted U.S. Composition Of Matter Patent For Direct AMPK Activator PXL770 For The Potential Treatment Of Type 2 Diabetes And Related Disorders 3/29/2016 11:12:31 AM
Poxel SAS Appoints Jonae R. Barnes As Senior Vice President Investor Relations And Public Relations, Based In Boston 3/14/2016 9:06:57 AM
Poxel SAS Appoints Janice Bourque And Pierre Legault To Its Board Of Directors 2/1/2016 10:25:41 AM
Poxel Release: Imeglimin’s Innovative Mitochondria-Targeted Mechanism Of Action Recognized By The Scientific Committee Of The World Mitochondria Society 11/2/2015 10:24:55 AM
Poxel SAS Raises $17 Million to Progress Imeglimin Development to Treat Type 2 Diabetes 12/18/2012 6:36:52 AM
New Clinical Results for an Anti-Diabetic Compound in Development at Poxel SAS 10/26/2011 8:58:53 AM
Poxel SAS Raises EUR16 million (USD 19.7 Million) in a Series A Financing to Accelerate Pipeline Development 7/8/2010 7:25:07 AM
Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 5/28/2009 11:22:48 AM